| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 286.0 | 180.9 |
| Profit before tax | 59.1 | 27.2 |
| Net income | 47.3 | 18.4 |
| EPS (diluted, $ a share) | $0.56 | $0.23 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +156.8% |
|---|---|
| Revenue, year on year | +58.1% |
| Operating margin | 19.0% |
10-Q filed with the SEC, NASDAQ: KNSA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Kiniksa Pharmaceuticals International, plc: key numbers
- Share price
- $95.11Close, Nov 17
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Kiniksa Pharmaceuticals International, plc
All →Kiniksa Pharmaceuticals International CAO Michael R. Megna Sells $1.11M of Stock
Michael R. Megna, CAO, sold 11,280 shares of Kiniksa Pharmaceuticals International, plc at $98.54 a share, worth $1.11M in total on Nov 9, 2026. Shares held after the trade: 12,697 (-47.0%).
- Value
- $1.11M
- Shares
- 11,280
- Price
- $98.54
- Role
- CAO
- Holding change
- -47.0%
- Trade date
- Nov 9, 2026
Kiniksa Pharmaceuticals International Chairman & CEO Sanj K. Patel Sells $14.3M of Stock
Sanj K. Patel, Chairman & CEO, sold 151,300 shares of Kiniksa Pharmaceuticals International, plc at $92.35 to $96.05 a share (average $94.71) in 5 transactions, worth $14.3M in total on Nov 4, 2026. Shares held after the trade: 774,500 (-3.4%).
- Value
- $14.3M
- Shares
- 151,300
- Average price
- $94.71
- Role
- Chairman & CEO
- Holding change
- -3.4%
- Trade date
- Nov 4, 2026
Kiniksa Pharmaceuticals International Chairman & CEO Sanj K. Patel Sells $37.4M of Stock
Sanj K. Patel, Chairman & CEO, sold 402,394 shares of Kiniksa Pharmaceuticals International, plc at $90.77 to $98.16 a share (average $92.92) in 14 transactions, worth $37.4M in total between Oct 30, 2026 and Nov 3, 2026. Shares held after the trade: 780,037 (-0.6%).
- Value
- $37.4M
- Shares
- 402,394
- Average price
- $92.92
- Role
- Chairman & CEO
- Holding change
- -0.6%
- Trade date
- Oct 30, 2026 to Nov 3, 2026
Kiniksa Pharmaceuticals International CFO Mark Ragosa Sells $3.39M of Stock
Mark Ragosa, CFO, sold 36,783 shares of Kiniksa Pharmaceuticals International, plc at $91.40 to $94.01 a share (average $92.16) in 4 transactions, worth $3.39M in total on Nov 2, 2026. Shares held after the trade: 20,854 (-1.0%).
- Value
- $3.39M
- Shares
- 36,783
- Average price
- $92.16
- Role
- CFO
- Holding change
- -1.0%
- Trade date
- Nov 2, 2026
Kiniksa Pharmaceuticals International CMO John F. Paolini Sells $8.94M of Stock
John F. Paolini, CMO, sold 96,000 shares of Kiniksa Pharmaceuticals International, plc at $92.02 to $97.77 a share (average $93.09) in 10 transactions, worth $8.94M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 69,922 (-1.0%).
- Value
- $8.94M
- Shares
- 96,000
- Average price
- $93.09
- Role
- CMO
- Holding change
- -1.0%
- Trade date
- Oct 30, 2026 to Nov 2, 2026
Kiniksa Pharmaceuticals International COO Ross Moat Sells $9.63M of Stock
Ross Moat, COO, sold 103,585 shares of Kiniksa Pharmaceuticals International, plc at $91.23 to $97.76 a share (average $92.93) in 11 transactions, worth $9.63M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 10,294 (-6.6%).
- Value
- $9.63M
- Shares
- 103,585
- Average price
- $92.93
- Role
- COO
- Holding change
- -6.6%
- Trade date
- Oct 30, 2026 to Nov 2, 2026